John F. Smyth

10.1k total citations
202 papers, 8.2k citations indexed

About

John F. Smyth is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, John F. Smyth has authored 202 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Molecular Biology, 86 papers in Oncology and 22 papers in Reproductive Medicine. Recurrent topics in John F. Smyth's work include Cancer therapeutics and mechanisms (30 papers), Ovarian cancer diagnosis and treatment (21 papers) and Cancer Treatment and Pharmacology (17 papers). John F. Smyth is often cited by papers focused on Cancer therapeutics and mechanisms (30 papers), Ovarian cancer diagnosis and treatment (21 papers) and Cancer Treatment and Pharmacology (17 papers). John F. Smyth collaborates with scholars based in United Kingdom, United States and Netherlands. John F. Smyth's co-authors include Simon P. Langdon, Jeffrey L. Cummings, Hani Gabra, G. D. CHISHOLM, Janet S. Macpherson, K. James, Steven A. Prescott, Robert Leonard, William R. Miller and T. B. Hargreave and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

John F. Smyth

198 papers receiving 7.9k citations

Peers

Countries citing papers authored by John F. Smyth

Since Specialization

Citations

This map shows the geographic impact of John F. Smyth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Smyth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Smyth more than expected).

Fields of papers citing papers by John F. Smyth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Smyth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Smyth. The network helps show where John F. Smyth may publish in the future.

Co-authorship network of co-authors of John F. Smyth

This figure shows the co-authorship network connecting the top 25 collaborators of John F. Smyth. A scholar is included among the top collaborators of John F. Smyth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Smyth. John F. Smyth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment 2011 ·Cancer Research ·Hagen Kulbe, Probir Chakravarty, David A. Leinster, Kellie A. Charles, Joseph Kwong, Richard G. Thompson, Jermaine Coward, Tiziana Schioppa, Stephen C. Robinson, William M. Gallagher, Laura Galletta, Michael A. Salako, John F. Smyth, Thorsten Hagemann, Donal J. Brennan, David D.L. Bowtell, Frances R. Balkwill	171
2	WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3 2009 ·Cancer Research ·Charlie Gourley, Adam J.W. Paige, Karen J. Taylor, (unknown), (unknown), Jieqing Zhang, Mingjun Sun, Szymon Janczar, David J. Harrison, Morwenna Muir, John F. Smyth, Hani Gabra	84
3	Comparison of strategies targeting Raf-1 mRNA in ovarian cancer 2005 ·International Journal of Cancer ·Peter Mullen, Fiona McPhillips, Brett P. Monia, John F. Smyth, Simon P. Langdon	7
4	Estrogen receptor-α mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen 2005 ·Endocrine Related Cancer ·Amanda O’Donnell, Kenneth G. MacLeod, David J. Burns, John F. Smyth, Simon P. Langdon	128
5	The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines 2005 ·European Journal of Cancer ·(unknown), I. Mayer, Simon P. Langdon, John F. Smyth, Duncan I. Jodrell, Sylvie M. Guichard	44
6	Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins 2003 ·Biochemical Pharmacology ·Jeffrey L. Cummings, Noam Zelcer, John Allen, Denggao Yao, Gary W. Boyd, (unknown), Thomas Friedberg, John F. Smyth, Duncan I. Jodrell	56
7	Malignant mixed mesodermal tumours 2002 ·European Journal of Cancer ·Charlie Gourley, A. Al‐Nafussi, Mohammad A. Abdulkader, John F. Smyth, Hani Gabra	10
8	High-Performance Liquid Chromatographic Technique for the Simultaneous Determination of Lactone and Hydroxy Acid Forms of Camptothecin and SN-38 in Tissue Culture Media and Cancer Cells 2001 ·Analytical Biochemistry ·Gary W. Boyd, John F. Smyth, Duncan I. Jodrell, Jeffrey L. Cummings	32
9	A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly 2000 ·European Journal of Cancer ·L. Dawson, Duncan I. Jodrell, A. Bowman, Ron Rye, (unknown), A. Bernareggi, Gabriella Camboni, John F. Smyth	33
10	Paracrine regulation of ovarian cancer by endothelin 1999 ·European Journal of Cancer ·(unknown), William R. Miller, John F. Smyth, Simon P. Langdon	30
11	Current Issues in the Enzymology of Mitomycin C Metabolic Activation 1998 ·General Pharmacology The Vascular System ·Victoria J. Spanswick, Jeffrey L. Cummings, John F. Smyth	22
12	Pharmacological and Biochemical Determinants of the Antitumour Activity of the Indoloquinone EO9 1998 ·Biochemical Pharmacology ·(unknown), Victoria J. Spanswick, J. Gardiner, Alison Ritchie, John F. Smyth	25
13	Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography 1996 ·Journal of Chromatography B Biomedical Sciences and Applications ·Jeffrey L. Cummings, (unknown), Janet S. Macpherson, John F. Smyth	5
14	Effect of Human Recombinant Interferon-α on the Activity of cis-Diamminedichloroplatinum(II) in Human Non-Small Cell Lung Cancer Xenografts 1995 ·Cancer Investigation ·(unknown), Angela Bowman, Kenneth G. MacLeod, Alison Ritchie, Jeffrey L. Cummings, John F. Smyth	2
15	Conducting clinical research in the new NHS: the model of cancer 1994 ·BMJ ·John F. Smyth, Jean Mossman, Richard Hall, Susan Hepburn, Ross Pinkerton, Marcus Richards, N. Thatcher, (unknown)	37
16	Determination of two neuropeptide growth factor antagonists, [d-Arg1,d-Phe5,d-Trp7,9,Leu11]-substance P and [Arg6, d-Trp7,9,N-MePhe8]-substance P(6–11), by high-performance liquid chromatography with electrochemical detection 1994 ·Journal of Chromatography B Biomedical Sciences and Applications ·Jeffrey L. Cummings, (unknown), Simon P. Langdon, Enrique Rozengurt, John F. Smyth	13
17	Estrogen and Anti-Estrogen Effects on the Growth of Human Epithelial Ovarian Cancer In Vitro 1989 ·American Journal of Obstetrics and Gynecology ·John D. Nash, Robert F. Ozols, John F. Smyth, Thomas C. Hamilton	74
18	Adult neuroblastoma report of three cases and review of the literature 1986 ·Cancer ·Simon Allan, M A Cornbleet, James Carmichael, S.J. Arnott, John F. Smyth	28
19	MALIGNANT MELANOMA IN SCOTLAND 1979-1983 1985 ·The Lancet ·R.M. MACKIE, David S. Soutar, A.C.H. Watson, K M McLaren, (unknown), Andrew W. Hutcheon, John F. Smyth, Kenneth C. Calman, John Hunter, Jenny MacGillivray, R Rankin, (unknown)	55
20	Paraneoplastic hypercalcaemia in ovarian carcinoma. 1984 ·BMJ ·(unknown), Stephen Lockhart, Renaud Léonard, John F. Smyth	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact